Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 StudyMyung‐Ju Ahn, Jaafar Bennouna, Kentaro Tanaka et al.|Journal of Clinical Oncology|2024Cited by 177
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01Toshio Shimizu, Rebecca S. Heist, Edward B. Garon et al.|Journal of Clinical Oncology|2023Cited by 168